Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH

FOSTER CITY, Calif. & BAGSVÆRD, Denmark–(BUSINESS WIRE)–Nov. 15, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat…